Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?

Nephrol Dial Transplant. 2004 Feb;19(2):288-93. doi: 10.1093/ndt/gfg489.
No abstract available

Publication types

  • Comparative Study
  • Editorial

MeSH terms

  • Autoantibodies / drug effects*
  • Autoantibodies / metabolism
  • Erythropoiesis / drug effects
  • Erythropoiesis / immunology*
  • Erythropoietin / adverse effects*
  • Erythropoietin / therapeutic use
  • Humans
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / diagnosis
  • Kidney Failure, Chronic / therapy
  • Prognosis
  • Recombinant Proteins
  • Red-Cell Aplasia, Pure / chemically induced*
  • Red-Cell Aplasia, Pure / prevention & control
  • Renal Dialysis / adverse effects
  • Renal Dialysis / methods
  • Risk Assessment
  • Severity of Illness Index

Substances

  • Autoantibodies
  • Recombinant Proteins
  • Erythropoietin